uniQure N.V. (QURE)
NASDAQ: QURE · Real-Time Price · USD
5.72
-0.59 (-9.28%)
Oct 31, 2024, 4:00 PM EDT - Market closed
uniQure Revenue
uniQure had revenue of $11.13M in the quarter ending June 30, 2024, with 359.37% growth. This brings the company's revenue in the last twelve months to $27.71M, down -75.25% year-over-year. In the year 2023, uniQure had annual revenue of $15.84M, down -85.12%.
Revenue (ttm)
$27.71M
Revenue Growth
-75.25%
P/S Ratio
10.96
Revenue / Employee
$57,723
Employees
480
Market Cap
278.55M
Revenue Chart
Revenue History
| Fiscal Year End | Revenue | Change | Growth |
|---|---|---|---|
| Dec 31, 2023 | 15.84M | -90.64M | -85.12% |
| Dec 31, 2022 | 106.48M | -417.52M | -79.68% |
| Dec 31, 2021 | 524.00M | 486.49M | 1,296.82% |
| Dec 31, 2020 | 37.51M | 30.23M | 415.23% |
| Dec 31, 2019 | 7.28M | -4.00M | -35.48% |
| Dec 31, 2018 | Pro | Pro | Pro |
| Dec 31, 2017 | Pro | Pro | Pro |
| Dec 31, 2016 | Pro | Pro | Pro |
| Dec 31, 2015 | Pro | Pro | Pro |
| Dec 31, 2014 | Pro | Pro | Pro |
Sources: Historical revenue is based on company filings submitted to the U.S. Securities and Exchange Commission (SEC). The most recent revenue numbers may be taken from company press releases.
Revenue Definition
Revenue, also called sales, is the amount of money a company receives from its business activities, such as sales of products or services. Revenue does not take any expenses into account and is therefore different from profits.
Full DefinitionRelated Stocks
| Company Name | Revenue |
|---|---|
| Aurora Cannabis | 203.84M |
| AirSculpt Technologies | 193.03M |
| Cerus | 169.98M |
| Kamada | 154.57M |
| iTeos Therapeutics | 35.00M |
| Fate Therapeutics | 12.32M |
QURE News
- 16 days ago - uniQure Announces Dosing of First Patient in Phase I/II Clinical Trial of AMT-162 for the Treatment SOD1-ALS - GlobeNewsWire
- 5 weeks ago - uniQure Announces Orphan Drug Designation Granted to AMT-191 for the Treatment of Fabry Disease - GlobeNewsWire
- 2 months ago - uniQure Announces Dosing of First Patient in Phase I/IIa Clinical Trial of AMT-191 for the Treatment of Fabry Disease - GlobeNewsWire
- 3 months ago - uniQure: Pullback After Strong Interim Treatment Data Creates Buying Opportunity - Seeking Alpha
- 3 months ago - uniQure Announces Second Quarter 2024 Financial Results and Provides Company Update - GlobeNewsWire
- 3 months ago - uniQure Announces Closing of Sale of Manufacturing Facility to Genezen - GlobeNewsWire
- 3 months ago - What Led To A 150% Rise In UniQure Stock In A Week? - Forbes
- 4 months ago - uniQure: Positive HD AMT-130 Treatment Data Leads To Several Other Catalysts - Seeking Alpha